Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 119   

Articles published

JNJ 106.59 +0.05 (0.05%)
price chart
Johnson & Johnson Buying Alios for $1.75B
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases.
Johnson & Johnson to Buy Biotech Company Alios BioPharma  New York Times
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma  MarketWatch
Related articles »  
Johnson & Johnson to buy private drug developer for $1.75 billion
(Reuters) - Johnson & Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a respiratory viral infection for which there is no approved treatment.
Johnson & Johnson buying Alios for $1.75 billion
... development at Janssen Pharmaceutical Cos. of Johnson & Johnson. The acquisition is targeted to close in the fourth quarter.
Johnson & Johnson buying Alios BioPharma for $1.75 billion
NEW BRUNSWICK, N.J. (AP) - Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.
Johnson & Johnson Is The Most Attractive Mega-Cap Pharma Stock For Income ...
This article compares four mega-cap pharmaceutical stocks with dividend yields above 2% and market caps above $150 billion. Johnson & Johnson's dividend growth history, conservative payout ratio and projected future growth are impressive.
UPDATE 1-Johnson & Johnson to buy private drug developer for $1.75 bln
(Adds background, details). Sept 30 (Reuters) - Johnson & Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a respiratory viral infection for which there is no approved treatment.
Johnson & Johnson to Quicken Development of Ebola Virus Vaccine
"The decision to accelerate the program is based on the fact that it is such a catastrophic situation in West Africa," said Dr.
Johnson & Johnson Pushes Ahead With Ebola Vaccine  NPR (blog)
Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate ...  MarketWatch
Related articles »  
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson Johnson & Johnson (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call ...
Related articles »  
How Will Johnson & Johnson (JNJ) Stock Be Affected by This Acquisition?
NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) shares are up 0.27% to $106.83 on Tuesday after the company announced that it is acquiring privately held drug developer Alios BioPharma for $1.75 billion dollars as the company looks to builds its viral ...
Alios BioPharma Announces Acquisition Agreement With Johnson & Johnson
SOUTH SAN FRANCISCO, CA, Sep 30, 2014 (Marketwired via COMTEX) -- Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, today announced a definitive agreement with Johnson & Johnson whereby ...